VISICORT partners NUI Galway, Orbsen, and Pintail are involved in NEPHSTROM, a new European project, which was launched last week. NEPHSTROM involves eleven partners from Ireland, the UK, Germany, and the Netherlands, and has received €6 million funding under the European Union’s Horizon 2020 funding programme. NEPHSTROM will evaluate the clinical safety and efficacy of a next-generation cell therapy discovered by Galway-based Orbsen Therapeutics, to combat diabetic kidney disease. Find out more about the project at www.nephstrom.eu.
This project has received funding from the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement no 602470. The material presented and views expressed here are the responsibility of the author(s) only. The EU Commission takes no responsibility for any use made of the information set out.